Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 6/20 | 0.46 |
| ▸ | GHSR | Q92847 | 5/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17864749 | 0.87 | MTNR1B (0.47) | MTNR1BGHSRMTNR1AMEN1KMT2A | |
| SCHEMBL17864845 | 0.85 | MTNR1B (0.45) | MTNR1BGHSRMTNR1AMEN1KMT2A | |
| SCHEMBL17864794 | 0.85 | MTNR1B (0.45) | MTNR1BGHSRMTNR1AMEN1KMT2A | |
| SCHEMBL17821736 | 0.82 | MTNR1B (0.55) | MTNR1BMTNR1AMEN1KMT2ALMNA | |
| SCHEMBL12394508 | 0.80 | MTNR1B (0.52) | MTNR1BGHSRMTNR1AMEN1KMT2A | |
| SCHEMBL17864748 | 0.79 | MTNR1B (0.46) | MTNR1BGHSRMTNR1AMEN1KMT2A | |
| SCHEMBL17821679 | 0.78 | MTNR1B (0.46) | MTNR1BGHSRMTNR1AMEN1KMT2A | |
| SCHEMBL17821749 | 0.78 | GHSR (0.54) | MTNR1BGHSRMTNR1AMEN1KMT2A | |
| SCHEMBL17864800 | 0.77 | MTNR1B (0.43) | MTNR1BGHSRMTNR1AMEN1KMT2A | |
| SCHEMBL17821818 | 0.77 | MTNR1B (0.45) | MTNR1BGHSRMTNR1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| WO-2016100391-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | MTNR1B 3891/4885GHSR 4858/4885MTNR1A 4263/4885 |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | MTNR1B 3891/4885GHSR 4858/4885MTNR1A 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.